Clinical Trial

Bone Quality Evolution in Medication-Related Osteonecrosis of the Jaw Assessed by CBCT (B-ONJ EVOL)

Study acronym: B-ONJ EVOL
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Medication-related osteonecrosis of the jaw (MRONJ) is a known complication of antiresorptive therapies such as bisphosphonates and denosumab. It can lead to bone damage in the jaw, with variable clinical outcomes depending on disease stage and management. Cone Beam Computed Tomography (CBCT) is currently recommended for diagnosis and follow-up of MRONJ. However, most studies rely on qualitative or descriptive imaging findings, and little is known about how bone quality evolves over time using quantitative imaging parameters. This retrospective multicenter study aims to describe the evolution of bone quality in patients with MRONJ using CBCT imaging. Bone parameters such as bone mineral density and trabecular structure will be measured at diagnosis and during follow-up. The study will help improve understanding of bone changes over time in MRONJ and may contribute to better assessment and management of the disease.
Trial Details
NCT Number NCT07588269
Lead Sponsor Nantes University Hospital
Conditions Medication-related Osteonecrosis of the Jaw, Osteonecrosis of the Jaw
Enrollment 25 participants
Start Date 2027-01
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-14